Why a Prostate Biopsy Is Recommended: The Numbers Behind the Decision
Prostate cancer is the second most common cancer in men globally. More than 1.4 million cases were diagnosed worldwide in 2020, with nearly 268,490 in the United States in 2022.
The five-year survival rate for localized prostate cancer exceeds 99 percent, which is why early detection through biopsy is one of the most consequential steps in men's health.
Not every elevated PSA (prostate-specific antigen) level means cancer. A PSA level below 4.0 ng/mL (nanograms per milliliter) is considered normal. But if it ranges between 4.0 and 10.0 ng/mL, the probability of prostate cancer is pretty high, around 25 percent.
If the levels are above 10.0 ng/mL, the risk is even higher than 50 percent. So doctors do not rely solely on PSA levels but combine them with digital rectal examination findings, PSA velocity, and multiparametric MRI (mpMRI) results before recommending a biopsy.
Also, doctors use a scoring system called PI-RADS to assess the likelihood that a lesion is cancerous on MRI, with scores ranging from 1 (very unlikely to be cancer) to 5 (highly suspicious). When that score comes back as a four or five, there is a 60 to 80 percent chance of cancer, and a biopsy is done next.
A score of one or two, on the other hand, usually means the lesion is low-risk enough to monitor with repeat imaging rather than move straight to a needle.
Types of Prostate Biopsy
The right approach depends on imaging findings, prior biopsy history, and infection risk.
Transrectal Ultrasound-Guided (TRUS) Biopsy:
-
This is the traditional method. A probe placed in the rectum guides a needle through the rectal wall to collect 10 to 12 tissue cores.
-
It takes about 10 to 20 minutes, but because the needle passes through the rectal wall, the infection risk is approximately 1 to 2%.
MRI-Fusion (Targeted) Biopsy:
-
In this procedure, a pre-procedure MRI (magnetic resonance imaging) is placed on a live ultrasound image, and the needle is carefully aimed at suspicious lesions found at PI-RADS (Prostate Imaging Reporting and Data System) three to five.
-
It lowers the overdiagnosis of slow-growing tumors and finds clinically important cancers more frequently than systematic sampling.
Transperineal Biopsy:
-
Instead of inserting the needle through the rectal wall, a transperineal biopsy uses the perineal skin. The infection rate decreases to about 0-0.5 percent because this skin can be completely cleansed.
-
When 20 to 40 cores are required following prior negative biopsies, saturation procedures are recommended for higher-risk patients.
How to Prepare?
Preparation covers four areas in the days leading up to the procedure.
Medications:
A few medications, like blood thinners, must be paused with physician approval. Aspirin and warfarin are usually stopped five to seven days before the procedure. NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) should be stopped three to five days beforehand. Newer anticoagulants such as rivaroxaban or apixaban two to three days before. Never stop prescribed medications without direct instruction from your doctor.
Antibiotics:
For transrectal biopsies, ciprofloxacin is prescribed two to three days after the procedure. Since fluoroquinolone resistance has been observed to exceed 20% in some populations, a few centers perform rectal swab cultures in advance to adjust antibiotic therapy accordingly.
Bowel Preparation:
A cleansing enema on the morning of the procedure reduces the bacterial load the needle travels through during a transrectal biopsy.
UTI Screening:
A urine sample is collected one to two weeks before to rule out active infection. If a UTI is present, the procedure is postponed until it clears, as proceeding carries a significantly elevated risk of sepsis.
The clinical team will check for bleeding disorders, review your entire prescription list, and note any allergies to latex, antibiotics, or anesthetics before beginning treatment. Once the doctor has explained the process, results, and risks, a written consent form will be signed.
During the Procedure
Step 1: Depending on the type of biopsy, the patient either lies on their left side or on their back with their legs supported.
Step 2: A lubricated ultrasound probe is gently introduced, and before any cores are taken, local anesthetic is injected into the nerves around the prostate. Once the anesthetic takes effect, the biopsy is done.
The needle passes are fast, each one taking less than a second, and patients typically feel pressure rather than sharpness with each pass.
Step 3: Tissue samples are collected, carefully labeled, and sent to the pathology lab. After that, the probe is removed, and the patient rests briefly before heading home.
Most people are in and out of the clinic within 60 to 90 minutes. IV sedation or general anesthesia is available for patients with significant anxiety or those undergoing saturation biopsies. Anyone receiving sedation must arrange a driver.
Risks and When to Seek Help
A few side effects are expected.
-
Blood in urine occurs in 60 to 80 percent of patients and resolves within 2 to 5 days.
-
Blood in semen can persist for four to six weeks and is not harmful.
-
Minor rectal bleeding resolves within 48 hours in most cases.
Infection risk is the more serious concern. For transrectal biopsies, sepsis requiring hospitalization occurs in 0.5 to 2 percent of cases. For transperineal biopsies, the rate approaches zero.
Contact your doctor or go to an emergency department if you experience:
-
Fever above 38 degrees Celsius (100.4 degrees Fahrenheit).
-
Chills or feeling severely unwell within 72 hours.
-
Complete inability to urinate.
-
Heavy rectal bleeding that does not slow within one to two hours.
-
Worsening pain not relieved by standard painkillers.
Understanding Your Results
Results are typically ready in 7 to 14 days. The pathology report uses specific terminology that is worth understanding before the follow-up appointment.
Adenocarcinoma:
It is the most common cancer type, found in over 95 percent of positive biopsies. The report notes how many cores are affected and what percentage of each core contains cancer cells.
Gleason Score and Grade Group:
These are the primary measures of cancer aggressiveness and guide treatment decisions based on risk level. Pathologists grade the two most prevalent cell patterns on a scale of 1 to 5 and sum them.
-
Score of 6 (3+3)- Grade Group 1: Represents low-risk disease where active surveillance is often the appropriate approach.
-
When the score rises to 7 (3+4), it falls into Grade Group 2: Indicating intermediate risk, where treatment is frequently considered.
-
A score of 7 (4+3) - Grade Group 3: Though similar to the previous grade, it carries an unfavorable intermediate risk, making treatment recommended in most cases.
-
Scores of 8 and above fall into Grade Groups 4 or 5: Representing high to very high risk disease, where prompt treatment is generally warranted to manage the condition effectively.
PIN (Prostatic Intraepithelial Neoplasia):
This describes pre-cancerous changes that may warrant a repeat biopsy within 12 months if high-grade.
ASAP (Atypical Small Acinar Proliferation):
ASAP means the cells looked suspicious, but the pathologist could not say for certain whether cancer was present or not. It is not a diagnosis, but it is not something to ignore either.
Around 4 in 10 to 6 in 10 men who get this result are found to have cancer when they go back for a second biopsy. For that reason, most doctors will recommend coming back within 3 to 6 months for another look.
A negative result substantially reduces the likelihood of significant cancer but does not entirely rule it out. PSA monitoring every 6 to 12 months remains important regardless of outcome.
What Happens Next?
If the result comes back positive but the cancer is low-risk, meaning a Gleason 6 or Grade Group 1, many urologists will recommend active surveillance rather than jumping straight to treatment. This means regular PSA checks every 3 to 6 months, a repeat biopsy every 1 to 2 years, and periodic MRI scans to monitor for any changes.
It is a structured approach, not a passive one, and most men on surveillance programs do not go on to need treatment for years, if at all. When the result shows a more aggressive cancer, the patient does not just see one doctor. A small team of specialists reviews the case together and develops the best plan.
The options usually include surgery to remove the prostate, radiation treatment, or medication to lower hormone levels that feed the cancer. What is recommended depends on how far the cancer has spread, the patient's age, and their overall health. The patient is part of that conversation throughout.
A negative result may sound good, but not for some men if the PSA is still rising or the MRI still looks off despite a clear biopsy. The doctor may suggest trying a different type of biopsy, along with a couple of extra blood tests, or simply keeping track with regular PSA checks and another MRI in the next year or two. It is not a reason to panic; it is just making sure nothing has been overlooked.
Conclusion
A prostate biopsy is a short, outpatient procedure that gives both the patient and their doctor the clearest possible picture of what is happening inside the prostate. For most men, the anticipation beforehand is significantly worse than the procedure itself. Knowing what to prepare, what to expect on the day, and how to interpret the results makes that experience far less daunting.
If your PSA is elevated, your MRI shows a suspicious finding, or your urologist has raised the possibility of a biopsy, the most important thing you can do is have that conversation with a specialist sooner rather than later.
Early and accurate diagnosis is where better outcomes begin.
Key Takeaways
-
Prostate cancer affects over 1.4 million men yearly, and a biopsy is the only test that confirms or rules it out.
-
PSA above 10.0 ng/mL means a greater than 50 percent cancer probability; a PI-RADS 4 or 5 on MRI pushes detection rates to 60 to 80 percent.
-
Taking antibiotics, stopping blood thinners on time, and treating any urinary infection before the procedure significantly reduce the risk.
-
Gleason 6 is low risk and usually indicates only monitoring; a score of 8 or higher indicates treatment should begin soon.
-
A clear biopsy does not always close the case; further PSA checks or a different type of biopsy may still be needed.
